Analysis of Risk Factors for Infusion-Related Reactions Following Rituximab Administration in Patients with Desensitization before Renal Transplantation-Reference-Cited by-同舟云学术

Analysis of Risk Factors for Infusion-Related Reactions Following Rituximab Administration in Patients with Desensitization before Renal Transplantation

Published:2023-09-01 Issue:9 Volume:46 Page:1332-1337
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biological & Pharmaceutical Bulletin

Author:

Nishiura Hironobu¹,Takahashi Masaya¹,Iwai Tomoaki²,Uchida Junji²,Nakamura Yasutaka¹

Affiliation:

1. Department of Pharmacy, Osaka Metropolitan University Hospital

2. Department of Urology, Osaka Metropolitan University Graduate School of Medicine

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/46/9/46_b23-00157/_pdf

Reference19 articles.

1. 1) Wood AM. Rituximab: an innovative therapy for non-Hodgkin’s lymphoma. Am. J. Health Syst. Pharm., 58, 215–229 (2001).

2. 2) Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376, 1164–1174 (2010).

3. 3) Tavakolpour S, Alesaeidi S, Darvishi M, GhasemiAdl M, Darabi-Monadi S, Akhlaghdoust M, Elikaei Behjati S, Jafarieh A. A comprehensive review of rituximab therapy in rheumatoid arthritis patients. Clin. Rheumatol., 38, 2977–2994 (2019).

4. 4) Iijima K, Sako DM, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet, 384, 1273–1281 (2014).

5. 5) Takahashi K, Saito K, Takahara S, Fuchinoue S, Yagisawa T, Aikawa A, Watarai Y, Yoshimura N, Tanabe K, Morozumi K, Shimazu M. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation. Clin. Exp. Nephrol., 21, 705–713 (2017).

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients with infusion-related reactions on fixed-dose rituximab treatment have higher body surface area than those without infusion-related reactions in adults with frequently relapsing minimal change nephrotic syndrome: a retrospective study;Journal of Pharmaceutical Health Care and Sciences;2024-02-22